Neukine Injection (300mcg), which contains the active ingredient Filgrastim, is a medication primarily used to stimulate the production of white blood cells in patients undergoing chemotherapy or those with certain bone marrow disorders. This injection is crucial for enhancing the body’s immune response, particularly in individuals whose white blood cell counts are low due to medical treatments or conditions. Filgrastim, a recombinant form of human granulocyte colony-stimulating factor (G-CSF), works by promoting the proliferation and differentiation of hematopoietic stem cells in the bone marrow, leading to increased production of neutrophils. Neukine Injection is typically administered subcutaneously and is available in a 300mcg dosage, making it a vital therapeutic option for patients at risk of infections due to neutropenia. Understanding the composition and purpose of Neukine Injection is essential for patients and healthcare providers alike, as it plays a significant role in managing the side effects of cancer treatments and improving overall patient outcomes.